- Title
- Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies
- Creators
- Neeraj Agarwal - University of UtahArun Azad - Monash UniversityAndre Fay - Pontifícia Universidade Católica do Rio Grande do SulJoan Carles - Vall d'Hebron Institute of OncologyNeal D. Shore - Carolina Urologic Research CenterLuke T. Nordquist - Urology Cancer Center and GU Research NetworkLawrence Ivan Karsh - The Urology Center of ColoradoCurtis Dunshee - Urology AssociatesSrinand Ponnathapura Nandakumar - Pfizer, Inc., San Francisco, CABeth Sullivan - Pfizer (United States)Akos Czibere - Pfizer (United States)Fong Wang - Pfizer (United States)Karim Fizazi - Institut Gustave Roussy
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.TPS5091-TPS5091
- Identifiers
- 991006262533702656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies
Journal of clinical oncology, Vol.36(15_suppl), pp.TPS5091-TPS5091
05/20/2018
Metrics
1 Record Views